Search the Newsreel

AXIS Capital Holdings (AXS) Following Earnings And Leadership Moves Still Looks Undervalued

AXIS Capital Holdings (AXS) appears undervalued despite a recent share price dip, trading at a discount to analyst targets and fair value checks. Recent Q2 2026 earnings, share buybacks, and new leadership appointments have provided new data for investors, with the company focusing on …

How Axsome Therapeutics Inc. (AXSM) Affects Rotational Strategy Timing

Axsome Therapeutics Inc. (AXSM) is analyzed through institutional trading strategies by Stock Traders Daily. The report identifies weak near and mid-term sentiment but a strong long-term outlook for AXSM, highlighting specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. AI-generated signals …

AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More

AXSOME THERAPEUTICS ($AXSM) is set to release its Q2 2026 earnings on August 10th, with analysts projecting revenues of $225.45 million and an EPS of -$0.86. The article details recent insider trading activity, showing 16 sales and zero purchases over the last six months …

Axsome Therapeutics, Inc. $AXSM Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Axsome Therapeutics by 3.2% in the first quarter, selling 19,942 shares and retaining 598,091 shares worth $101.1 million. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a $265.55 price target. Over …

AXIS Capital Holdings Ltd (AXS) Stock News Today

This article provides current stock information for AXIS Capital Holdings Ltd (AXS), noting its latest closing price, market cap, and P/E TTM. It states that more news regarding the company's stock, earnings, analyst ratings, and key developments will be available soon. The piece encourages …

Axsome therapeutics CEO Herriot Tabuteau sells $10.5m in shares

Axsome Therapeutics CEO Herriot Tabuteau sold approximately $10.5 million worth of common stock on August 5 and 6, 2026, following the exercise of stock options that were nearing their expiration date. These transactions were executed under a pre-approved 10b5-1 trading plan. Despite the sales, …

Axis Capital Holdings Limited (AXS) Stock Price, News, Quote & History

This article provides a comprehensive overview of Axis Capital Holdings Limited (AXS), detailing its stock performance, key financial metrics, and company profile. It includes recent news, analyst recommendations, and a comparison with similar companies in the insurance-specialty industry. The data presented covers trading activity …

AXIS Capital Holdings Ltd (AXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

AXIS Capital Holdings Ltd (AXS) has an earnings forecast score of 7.38, ranking 39th in the Insurance industry. Analysts have set an average price target of $115.50 for AXS, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is …

Axsome Therapeutics (AXSM) Stock Looks Near Fair Value Despite Premium Sales Pricing

Axsome Therapeutics (AXSM) stock appears to be priced near its fair value, despite its premium sales pricing, following a significant 5-year gain and a recent pullback. The company's P/S ratio of 15.3x is higher than industry averages but aligns closely with its estimated fair …

AXSM (AXSM) holder files to sell 4,660 shares via cashless option exercise

A holder of Axsome Therapeutics (AXSM) has filed a Form 144 to sell 4,660 common shares through a cashless option exercise, valued at approximately $979,205.80. These shares, acquired in 2017 as compensation via stock options, are intended for sale on or after August 6, …

AXIS Capital (AXS) Stock Looks Undervalued Despite Strong Returns And Deal Risk

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AXIS Capital Holdings has delivered a strong 123.4% return over the past 5 years, yet its valuation checks currently lean cheap rather than stretched. With …

Axsome Therapeutics (AXSM) insider plans 45,004-share cashless option sale

Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026. The shares were originally acquired as compensation …

DUAL's John Kopach Will Join AXIS as Head of Wholesale Lower Middle Market

AXIS Capital has agreed to acquire the renewal rights to DUAL North America's Excess Liability business, a move that strengthens AXIS's Casualty platform. As part of this transaction, John Kopach, previously Executive Vice President of DUAL Excess Liability, will join AXIS as the Head …

AXIS Agrees to Acquire Renewal Rights to DUAL North America's Excess Liability Business

AXIS Specialty US Services Inc. Acquisition Strengthens AXIS' Casualty Platform with High-Performing Book, Ensuring Continuity for Brokers and Policyholders PEMBROKE, Bermuda, Aug. 05, 2026 (GLOBE NEWSWIRE) -- AXIS Capital (NYSE: AXS) today announced it has agreed to acquire the renewal rights to the Excess …

Axsome Therapeutics Inc (AXSM) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates related to Axsome Therapeutics Inc (AXSM), focusing on its upcoming Q2 earnings, FDA approvals, and ongoing clinical trials. It also includes several Zacks reports placing AXSM on a "Strong Sell" list. Additionally, it …

DOWLING & PARTN Estimates Axis Capital FY2028 Earnings

KBW Maintains Axis Capital Holdings(AXS.US) With Buy Rating, Cuts Target Price to $125

KBW has reiterated its Buy rating on Axis Capital Holdings (AXS.US) but has adjusted its target price downwards to $125. This indicates a continued positive outlook on the stock, albeit with a revised valuation.

California State Teachers Retirement System Grows Holdings in Axis Capital Holdings Limited $AXS

The California State Teachers Retirement System increased its stake in Axis Capital Holdings Limited by 25.7% in the first quarter, now holding 92,474 shares valued at approximately $9.38 million. Axis Capital reported quarterly revenue of $1.75 billion, a 7.4% year-over-year increase, but its earnings …

Axis Capital Holdings Limited (NYSE:AXS) Given Average Rating of "Moderate Buy" by Analysts

Eleven analysts have given Axis Capital Holdings Limited (NYSE:AXS) a "Moderate Buy" consensus rating, with an average 12-month price target of $121, higher than its current price of $105.82. The company reported a 7.4% year-over-year revenue increase to $1.75 billion, though its $2.84 EPS …

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Axsome Therapeutics (AXSM) is projected to report higher Q2 2026 revenue but lower year-over-year earnings, leading to investor scrutiny regarding its profitability amidst pipeline expansion. The company's investment narrative centers on its CNS franchise eventually translating rising revenues into sustainable profitability, with an FDA …

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% After Analyst Downgrade

Axsome Therapeutics (NASDAQ:AXSM) shares dropped 4% after Mizuho lowered its price target from $310 to $306, while still maintaining an "outperform" rating. Despite missing adjusted earnings expectations with a loss of $1.26 per share, the company reported a 57.4% year-over-year revenue increase to $191.2 …

AXIS Capital Is Maintained at Outperform by Mizuho

Mizuho has reiterated its "Outperform" rating on AXIS Capital. The analyst firm continues to view AXIS Capital favorably, maintaining its positive outlook on the company's stock.

Axsome Therapeutics, Inc. (AXSM): Investor Outlook on a Biotech Stock with a 29% Potential Upside

Axsome Therapeutics (AXSM) is a biotech company focused on CNS disorders with a market capitalization of $11.22 billion. Despite negative EPS and ROE, the company has strong analyst ratings, an average target price suggesting a 29.51% upside, and robust revenue growth of 57.40%. Its …

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics (AXSM) to Announce Earnings on Monday

Axsome Therapeutics (NASDAQ: AXSM) is scheduled to announce its Q2 2026 earnings before the market opens on Monday, August 10th. Analysts anticipate a loss of $0.8921 per share and revenue of $221.1 million. Despite a previous EPS miss, revenue increased by 57.4% year-over-year, and …

Axsome Therapeutics Inc (0HKF) Q3 2025 Earnings Report - Results, Call & Slides

Axsome Therapeutics (0HKF) released its Q3 2025 earnings report, missing consensus EPS estimates with an actual EPS of -$0.94 against an expected -$0.86. However, the company beat revenue expectations, reporting $170.99M against an expected $162.67M, marking a significant 63.22% year-over-year revenue growth. The earnings …

Axsome Therapeutics, Inc. $AXSM Stock Holdings Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 12.5% in the first quarter, selling 16,791 shares. Despite this, institutional investors collectively own 81.49% of the company, with many major funds increasing their positions. Axsome Therapeutics reported revenue of $191.2 …

Quantinno Capital Management LP Has $32.30 Million Stake in Axis Capital Holdings Limited $AXS

Quantinno Capital Management LP significantly increased its stake in Axis Capital Holdings Limited by 64% in the first quarter, now holding 318,539 shares valued at $32.3 million. Despite missing earnings per share estimates, Axis Capital reported a 7.4% year-over-year revenue increase and offers a …

Sei Investments Co. Buys 22,464 Shares of Axsome Therapeutics, Inc. $AXSM

Sei Investments Co. significantly increased its stake in Axsome Therapeutics, Inc. by 47.2% in the first quarter, acquiring an additional 22,464 shares, bringing its total to 70,064 shares valued at $11.8 million. This move is part of broader institutional interest, with hedge funds and …

AXIS Capital Holdings Limited 2026 Q2 - Results - Earnings Call Presentation (NYSE:AXS) 2026-07-31

AXIS Capital Holdings Limited (NYSE:AXS) released its Q2 2026 earnings call presentation on July 31, 2026. The company reported an EPS of $2.84, missing estimates by $0.40, and revenue of $1.61 billion, a 1.81% year-over-year decrease, missing estimates by $113.05 million. This article provides …

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

Mizuho has adjusted its price target for Axsome Therapeutics (AXSM) to $306 from $310, while maintaining an Outperform rating on the stock. This revision comes as part of their ongoing analysis of the biopharmaceutical company.

Mizuho Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Mizuho lowered its price target for Axsome Therapeutics (NASDAQ:AXSM) from $310 to $306, while maintaining an "outperform" rating, indicating a potential 40% upside. This comes after the company reported a quarterly loss of $1.26 per share, missing expectations, despite a 57.4% year-over-year revenue increase …

Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis

Axsome Therapeutics Inc (AXSM) has a stable financial status and high operating efficiency, with its financial score at 8.07, ranking 74 out of 155 in the Pharmaceuticals industry. The company reported a latest quarterly revenue of $191.20M, marking a 57.42% year-over-year increase, and an …

Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Axsome Therapeutics Inc (AXSM), detailing its price momentum score of 3.33, ranking 111 out of 155 in the Pharmaceuticals industry. It highlights the stock's current trading range between resistance at $251.09 and support at $219.70, suggesting suitability …

AXIS Capital Holdings Ltd (AXS) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of AXIS Capital Holdings Ltd (AXS), noting its stable financial status and high operating efficiency with a current score of 7.33, ranking 40th in the insurance industry. It highlights a recent quarterly revenue of $1.75 billion, marking …

Renaissance Technologies LLC Sells 5,700 Shares of Axsome Therapeutics, Inc. $AXSM

Renaissance Technologies LLC reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.4% in the first quarter, selling 5,700 shares and now owning 164,300 shares worth $27.77 million. Despite this, several other institutional investors increased their holdings, and analysts have a "Moderate Buy" rating with …